Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


TGF-β Pathway as a Therapeutic Target in Bone Metastases

Author(s): Patricia Juarez and Theresa A. Guise

Affiliation: Department of medicine, Division of Endocrinology, Indiana University, Indianapolis, Indiana, USA.


Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.

Keywords: TGF-β, TGF-β receptors, bone, metastases, TGF-β inhibitors, bone metastases, breast cancer, prostatic cancer, melanoma

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1301 - 1312]
Pages: 12
DOI: 10.2174/138161210791034049
Price: $58